Lead
A large observational study published on 18 March 2026 in BMJ Medicine by Washington University School of Medicine reports that interruptions in GLP‑1 therapy are linked to higher rates of heart attack, stroke and all‑cause death among adults with Type 2 diabetes. Researchers tracked electronic health records for more than 333,000 people with diabetes over three years, most using semaglutide products such as Ozempic. Continuous GLP‑1 use over three years was associated with an 18% lower cardiovascular risk; stopping treatment for six months or longer substantially reduced that protection. The study warns some cardiovascular benefits take years to accrue but may be lost much faster when therapy is discontinued.
Key takeaways
- WashU Medicine followed 333,000+ adults with Type 2 diabetes via electronic health records across a three‑year period, with the majority using Novo Nordisk’s semaglutide injections.
- Patients who remained on GLP‑1 therapy for three years experienced an 18% reduction in cardiovascular events relative to non‑discontinuers.
- A discontinuation of about six months largely erased that advantage, corresponding to a 4% higher cardiovascular risk versus continuous users.
- A treatment gap of two years was associated with a 22% higher cardiovascular risk compared with sustained GLP‑1 use.
- GLP‑1 discontinuation rates reported in prior studies range widely, from about 36% up to 81%, driven by access barriers and tolerability issues such as nausea.
- The authors describe a rapid reversal of metabolic gains after stopping therapy—improvements built over years can be undone in months.
- Policy moves—including planned Medicare coverage and employer initiatives—could reduce access barriers, but the study highlights the need for care systems to support long‑term adherence.
Background
Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs), notably semaglutide formulations marketed as Ozempic and Wegovy, have become widely used for diabetes and obesity management in the U.S.; roughly one in eight adults now takes a GLP‑1 class product. Clinical trials and regulatory decisions have increasingly recognized cardiovascular benefits: in 2024 the U.S. Food and Drug Administration approved semaglutide to reduce major cardiovascular events for certain adults with established heart disease and obesity. That regulatory shift positioned GLP‑1s not only as metabolic agents but also as cardiovascular risk modifiers.
Despite growing evidence and demand, real‑world persistence is uneven. Patients stop these therapies for many reasons—cost, limited insurance coverage, supply constraints, and gastrointestinal side effects are commonly cited. Prior observational work has shown discontinuation proportions that vary widely across settings and follow‑up lengths, complicating interpretation of long‑term population impact. The new WashU analysis attempts to quantify clinical consequences of those interruptions at scale.
Main event
The study used de‑identified electronic health records to follow more than 333,000 adults with Type 2 diabetes for three years, tracking prescription patterns and cardiovascular outcomes. Investigators compared outcomes for patients who maintained continuous GLP‑1 treatment against those who experienced gaps of varying lengths. Most patients in the cohort were prescribed semaglutide‑based injections produced by Novo Nordisk, reflecting market share during the study interval.
Key findings showed that continuous therapy correlated with an 18% lower rate of cardiovascular events over the study window. When patients stopped GLP‑1 therapy for around six months, that protective effect was largely lost: the discontinuers faced about a 4% higher cardiovascular risk than those who remained on treatment. Longer interruptions were associated with still greater risk: a two‑year lapse corresponded with roughly a 22% higher risk compared with sustained users.
Study authors framed the effect as asymmetric: building cardiovascular benefit appears to require prolonged exposure, while much shorter treatment interruptions can undo gains. The team controlled for measured clinical covariates in their models, but as with all observational analyses they noted residual confounding could remain. The paper was published in BMJ Medicine on 18 March 2026 and accompanied by a Washington University release summarizing clinical implications.
Analysis & implications
Clinically, the observations underscore that GLP‑1s deliver more than weight loss; investigators link their benefits to reductions in blood pressure, cholesterol, insulin resistance and inflammation—all plausible mediators of cardiovascular risk. If those physiologic improvements revert quickly when medication is stopped, patients may experience a rebound in risk factors that accelerate cardiovascular events. That dynamic helps explain why relatively brief treatment gaps translated into measurable changes in event rates.
From a health‑system perspective, the findings elevate adherence and continuity of care from convenience issues to patient‑safety priorities. High discontinuation rates—reported in prior studies between 36% and 81%—suggest many patients face clinical and structural barriers that undermine long‑term benefit. Addressing tolerability through proactive side‑effect management, improving access through insurance coverage and supply strategies, and designing follow‑up pathways to re‑start therapy promptly could reduce the population burden.
Policy changes may partially mitigate access barriers. U.S. Medicare preparing to cover weight‑loss treatments and employer negotiation for better benefits could expand sustained access, while manufacturers and clinicians aim to develop or refine agents with fewer adverse effects. Economically, sustained GLP‑1 use that prevents cardiovascular events could reduce downstream hospitalizations, but payers and employers will weigh upfront drug costs against long‑term savings.
Comparison & data
| Exposure group | Cardiovascular risk vs sustained GLP‑1 users |
|---|---|
| Continuous GLP‑1 use (3 years) | –18% (reduced risk) |
| 6‑month discontinuation | +4% (higher risk vs continuous) |
| 2‑year discontinuation | +22% (higher risk vs continuous) |
The table summarizes the study’s principal numeric comparisons. The 18% figure refers to the relative reduction in cardiovascular events observed among patients who maintained GLP‑1 therapy compared with those who did not discontinue; the +4% and +22% values reflect higher event risks observed in groups with treatment gaps of six months and two years, respectively, when measured against continuous users. These are relative comparisons from observational data and do not imply precise causal magnitudes for individual patients.
Reactions & quotes
GLP‑1 medicines provide broad metabolic benefits that extend beyond weight loss, and stopping them can quickly reverse those gains, increasing cardiovascular risk.
Dr. Ziyad Al‑Aly, WashU Medicine (study author)
Regulatory recognition in 2024 that semaglutide reduces major cardiovascular events expanded clinical indications, but real‑world continuity is essential to realize those benefits at scale.
Regulatory summary (U.S. Food and Drug Administration)
Patients and providers should plan for long‑term management of tolerability and access; intermittent treatment is unlikely to deliver the same cardiovascular protection as sustained use.
Cardiology and diabetes care commentary (expert consensus)
Unconfirmed
- Whether all GLP‑1 formulations carry identical durability of cardiovascular benefits remains unconfirmed; head‑to‑head long‑term comparative trials are limited.
- The precise biological timeline for loss and regain of cardiovascular protection after stopping and restarting therapy is not fully established and requires prospective study.
- The extent to which unmeasured confounding (for example, reasons for stopping therapy) explains observed risk differences cannot be entirely ruled out from this observational dataset.
Bottom line
The WashU BMJ Medicine analysis of 333,000+ adults with Type 2 diabetes finds that continuous GLP‑1 therapy is associated with substantially lower cardiovascular risk and that treatment interruptions—even relatively brief ones—can erode that protection. Clinicians and health systems should treat continuity as a therapeutic priority and address access and tolerability barriers proactively to preserve population‑level cardiovascular gains.
For patients considering GLP‑1 therapy, the study supports planning for long‑term management rather than short courses. Policymakers, payers and manufacturers can all play roles in improving sustained access and minimizing preventable lapses that may translate into excess heart attacks, strokes and deaths.
Sources
- CNBC — Healthy Returns newsletter coverage (media)
- BMJ Medicine — journal homepage; study published 18 March 2026 (academic journal)
- Washington University School of Medicine — institutional press release and study information (academic/official)
- U.S. Food and Drug Administration — semaglutide approval summary, 2024 (official regulator)